Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;40(1):10-38.
doi: 10.2337/cd22-as01.

Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers

American Diabetes Association

Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers

American Diabetes Association. Clin Diabetes. 2022 Jan.
No abstract available

PubMed Disclaimer

Figures

FIGURE 4.1
FIGURE 4.1
Decision cycle for patient-centered glycemic management in type 2 diabetes. HbA1c, glycated hemoglobin. Adapted from Davies MJ, D’Alessio DA, Fradkin J, et al. Diabetes Care 2018;41:2669–2701.
FIGURE 6.1
FIGURE 6.1
Key points included in standard AGP report. Reprinted from Holt RIG, DeVries JH, Hess-Fischl A, et al. Diabetes Care 2021;44:2589–2625.
FIGURE 9.3
FIGURE 9.3
Pharmacologic treatment of hyperglycemia in adults with type 2 diabetes. 2022 ADA Professional Practice Committee (PPC) adaptation of Davies MJ, D’Alessio DA, Fradkin J, et al. Diabetes Care 2018;41:2669–2701 and Buse JB, Wexler DJ, Tsapas A, et al. Diabetes Care 2020;43:487–493. For appropriate context, see Figure 4.1. The 2022 ADA PPC adaptation emphasizes incorporation of therapy rather than sequential add-on, which may require adjustment of current therapies. Therapeutic regimen should be tailored to comorbidities, patient-centered treatment factors, and management needs. Refer to sections 10 and 11 in the complete 2022 Standards of Care for detailed discussions of CVD and CKD risk management. CVOT, cardiovascular outcomes trial; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, sodium–glucose cotransporter 2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione.
See this image and copyright information in PMC